SCHEMBL13339652

SCHEMBL13339652

Cc1ccc2c(C(=O)O)c(N)sc2n1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IKBKB O14920 1/20 0.55
LIMK1 P53667 1/20 0.55
MAPT P10636 5/20 0.52
NPC1 O15118 4/20 0.52
RAB9A P51151 3/20 0.52
ALDH1A1 P00352 5/20 0.50
NPSR1 Q6W5P4 1/20 0.50
KDM4E B2RXH2 4/20 0.45
SMN1; SMN2 Q16637 3/20 0.45
USP28 Q96RU2 9/20 0.44
USP25 Q9UHP3 8/20 0.44
HPGD P15428 3/20 0.43
USP2 O75604 1/20 0.43
HSD17B10 Q99714 1/20 0.43
LMNA P02545 2/20 0.39
TP53 P04637 1/20 0.39
GAA P10253 1/20 0.39
NFKB1 P19838 1/20 0.39
NFKB2 Q00653 1/20 0.39
RELA Q04206 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL3494184 0.92 IKBKB (0.48) IKBKBLIMK1MAPTNPC1RAB9A
SCHEMBL29707312 0.77 LIMK1 (0.77) IKBKBLIMK1MAPTNPC1RAB9A
SCHEMBL19212039 0.77 LIMK1 (0.77) IKBKBLIMK1MAPTNPC1RAB9A
SCHEMBL13636496 0.77 USP28 (0.37) IKBKBLIMK1MAPTNPC1RAB9A
SCHEMBL3494185 0.77 IKBKB (0.45) IKBKBLIMK1MAPTNPC1RAB9A
SCHEMBL20731982 0.75 ALDH1A1 (0.62) IKBKBLIMK1MAPTNPC1RAB9A
SCHEMBL14399030 0.73 ALDH1A1 (0.56) IKBKBLIMK1MAPTNPC1RAB9A
SCHEMBL3492612 0.71 IKBKB (0.55) IKBKBLIMK1MAPTNPC1RAB9A
SCHEMBL12562427 0.71 LIMK1 (0.77) IKBKBLIMK1MAPTNPC1RAB9A
SCHEMBL16071461 0.71 IKBKB (1.00) IKBKBLIMK1MAPTNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100113418-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-05-06 US disclosed
US-20100113418-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-05-06 US disclosed
US-20100093777-A1 SPIRO-RING COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-04-15 US disclosed
US-20100093777-A1 SPIRO-RING COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-04-15 US disclosed
EP-2123652-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2009-11-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093777-A1 SPIRO-RING COMPOUND ACACA, PC, ACACB IKBKB 874/4885LIMK1 1763/4885MAPT 3618/4885
US-20100113418-A1 HETEROCYCLIC COMPOUND ACACA, ACAT1, CPT1B IKBKB 567/4885LIMK1 1204/4885MAPT 3905/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.